Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Switzerland | Healthcare | Pharmaceuticals | CHF 506.80B | 45.5x | 0.52 | CHF 560 | -7.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 227.89B | 21.6x | -2.07 | CHF 268.80 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.2% Upside | Upgrade to Pro+ | |
Roche Holding Participation | Switzerland | Healthcare | Pharmaceuticals | CHF 217.17B | 22.6x | -2.06 | CHF 256 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 193.86B | 18x | -1.4 | CHF 100.22 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.8% Downside | Upgrade to Pro+ | |
Novartis | Switzerland | Healthcare | Pharmaceuticals | CHF 193.86B | 18x | -1.4 | CHF 100.26 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sandoz | Switzerland | Healthcare | Pharmaceuticals | CHF 20.65B | 113.4x | 0.04 | CHF 48.29 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.1% Downside | Upgrade to Pro+ | |
Galenica Sante | Switzerland | Healthcare | Pharmaceuticals | CHF 4.18B | 21.7x | 2.53 | CHF 83.90 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.4% Upside | Upgrade to Pro+ | |
Dottikon Es Holding AG | Switzerland | Healthcare | Pharmaceuticals | CHF 4.13B | 39.1x | 1.27 | CHF 299 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
Siegfried Holding Ltd | Switzerland | Healthcare | Pharmaceuticals | CHF 3.83B | 23.5x | 0.59 | CHF 87.90 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.7% Upside | Upgrade to Pro+ | |
Joincare Pharmaceutical DRC | Switzerland | Healthcare | Pharmaceuticals | CHF 2.67B | 15.9x | -5.14 | CHF 6.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
COSMO Pharma | Switzerland | Healthcare | Pharmaceuticals | CHF 910.11M | 16.5x | CHF 57.10 | 2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44% Upside | Upgrade to Pro+ | ||
PolyPeptide Group AG | Switzerland | Healthcare | Pharmaceuticals | CHF 897.37M | -28.3x | 1.41 | CHF 28.45 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
Santhera Pharmaceuticals Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 178.40M | -3.8x | 0.02 | CHF 13.90 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Curatis Holding | Switzerland | Healthcare | Pharmaceuticals | CHF 57.41M | CHF 11.50 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |